Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- pain -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (86)	6/26/2009 9:44:31 AM
From: kenhott	Read Replies (1) \| Respond to of 101

Given it was an early stage partnership, I think you can expect the terms to be early stage terms. I don't think anyone knows the % outside of the companies. The Woods article in Nature came out in 2006. The partnership between Icagen and PFE was in 2007. It is certainly possible that they are working on the target. I think the article points out that the big boys are not in clinic at this point. I don't think it is exactly easy to get this just right. Icagen had a partnership with Abbott and they had someting working on Nav1.8. Even though Nav1.7 is the better target, they were looking at Nav1.8 for cold temperature related pain. I think the candidate was A-803467?? Not sure where it is at this point, likely died. You crossed linked this from CVTX so I guess you know that Ranolazine blocks Nav1.7, and other channels.